377 related articles for article (PubMed ID: 25617726)
21. Efficacy of microbial cell preparation in improving chronic constipation: a randomized, double-blind, placebo-controlled trial.
Jayasimhan S; Yap NY; Roest Y; Rajandram R; Chin KF
Clin Nutr; 2013 Dec; 32(6):928-34. PubMed ID: 23561636
[TBL] [Abstract][Full Text] [Related]
22. Gut Microbiota Composition Changes in Constipated Women of Reproductive Age.
Li H; Chen J; Ren X; Yang C; Liu S; Bai X; Shan S; Dong X
Front Cell Infect Microbiol; 2020; 10():557515. PubMed ID: 33552996
[TBL] [Abstract][Full Text] [Related]
23. Relationship Between Microbiota of the Colonic Mucosa vs Feces and Symptoms, Colonic Transit, and Methane Production in Female Patients With Chronic Constipation.
Parthasarathy G; Chen J; Chen X; Chia N; O'Connor HM; Wolf PG; Gaskins HR; Bharucha AE
Gastroenterology; 2016 Feb; 150(2):367-79.e1. PubMed ID: 26460205
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid Class.
Webster LR; Brewer RP; Lichtlen P; Losch-Beridon T; Mareya S; Wang M
Pain Med; 2018 Jun; 19(6):1195-1205. PubMed ID: 29897589
[TBL] [Abstract][Full Text] [Related]
25. Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS.
Attaluri A; Jackson M; Valestin J; Rao SS
Am J Gastroenterol; 2010 Jun; 105(6):1407-11. PubMed ID: 19953090
[TBL] [Abstract][Full Text] [Related]
26. Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: A prospective randomized pilot study in healthy volunteers.
Kato T; Honda Y; Kurita Y; Iwasaki A; Sato T; Kessoku T; Uchiyama S; Ogawa Y; Ohkubo H; Higurashi T; Yamanaka T; Usuda H; Wada K; Nakajima A
PLoS One; 2017; 12(4):e0175626. PubMed ID: 28410406
[TBL] [Abstract][Full Text] [Related]
27. Unveiling the gut microbiota composition and functionality associated with constipation through metagenomic analyses.
Mancabelli L; Milani C; Lugli GA; Turroni F; Mangifesta M; Viappiani A; Ticinesi A; Nouvenne A; Meschi T; van Sinderen D; Ventura M
Sci Rep; 2017 Aug; 7(1):9879. PubMed ID: 28852182
[TBL] [Abstract][Full Text] [Related]
28. Lubiprostone increases spontaneous bowel movement frequency and quality of life in patients with chronic idiopathic constipation.
Fukudo S; Hongo M; Kaneko H; Takano M; Ueno R
Clin Gastroenterol Hepatol; 2015 Feb; 13(2):294-301.e5. PubMed ID: 25158925
[TBL] [Abstract][Full Text] [Related]
29. Effect of High versus Low Dairy Consumption on the Gut Microbiome: Results of a Randomized, Cross-Over Study.
Swarte JC; Eelderink C; Douwes RM; Said MY; Hu S; Post A; Westerhuis R; Bakker SJL; Harmsen HJM
Nutrients; 2020 Jul; 12(7):. PubMed ID: 32708991
[TBL] [Abstract][Full Text] [Related]
30. Alteration of the Intestinal Environment by Lubiprostone Is Associated with Amelioration of Adenine-Induced CKD.
Mishima E; Fukuda S; Shima H; Hirayama A; Akiyama Y; Takeuchi Y; Fukuda NN; Suzuki T; Suzuki C; Yuri A; Kikuchi K; Tomioka Y; Ito S; Soga T; Abe T
J Am Soc Nephrol; 2015 Aug; 26(8):1787-94. PubMed ID: 25525179
[TBL] [Abstract][Full Text] [Related]
31. Lubiprostone for chronic constipation in adults.
Drug Ther Bull; 2014 Apr; 52(4):42-4. PubMed ID: 24722574
[TBL] [Abstract][Full Text] [Related]
32. Altered gut microbiota and short chain fatty acids in Chinese children with autism spectrum disorder.
Liu S; Li E; Sun Z; Fu D; Duan G; Jiang M; Yu Y; Mei L; Yang P; Tang Y; Zheng P
Sci Rep; 2019 Jan; 9(1):287. PubMed ID: 30670726
[TBL] [Abstract][Full Text] [Related]
33. A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial.
Pinheiro I; Robinson L; Verhelst A; Marzorati M; Winkens B; den Abbeele PV; Possemiers S
BMC Complement Altern Med; 2017 Sep; 17(1):441. PubMed ID: 28870194
[TBL] [Abstract][Full Text] [Related]
34. Prebiotics Improved the Defecation Status via Changes in the Microbiota and Short-chain Fatty Acids in Hemodialysis Patients.
Miyoshi M; Shiroto A; Kadoguchi H; Usami M; Hori Y
Kobe J Med Sci; 2020 Apr; 66(1):E12-E21. PubMed ID: 32814753
[TBL] [Abstract][Full Text] [Related]
35. Effects of different oligosaccharides at various dosages on the composition of gut microbiota and short-chain fatty acids in mice with constipation.
Wang L; Hu L; Yan S; Jiang T; Fang S; Wang G; Zhao J; Zhang H; Chen W
Food Funct; 2017 May; 8(5):1966-1978. PubMed ID: 28475191
[TBL] [Abstract][Full Text] [Related]
36. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome.
Chassard C; Dapoigny M; Scott KP; Crouzet L; Del'homme C; Marquet P; Martin JC; Pickering G; Ardid D; Eschalier A; Dubray C; Flint HJ; Bernalier-Donadille A
Aliment Pharmacol Ther; 2012 Apr; 35(7):828-38. PubMed ID: 22315951
[TBL] [Abstract][Full Text] [Related]
37. Function and clinical implications of short-chain fatty acids in patients with mixed refractory constipation.
Shi Y; Chen Q; Huang Y; Ni L; Liu J; Jiang J; Li N
Colorectal Dis; 2016 Aug; 18(8):803-10. PubMed ID: 26921846
[TBL] [Abstract][Full Text] [Related]
38. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety.
Johanson JF; Ueno R
Aliment Pharmacol Ther; 2007 Jun; 25(11):1351-61. PubMed ID: 17509103
[TBL] [Abstract][Full Text] [Related]
39. Lubiprostone for constipation in adults with cystic fibrosis: a pilot study.
O'Brien CE; Anderson PJ; Stowe CD
Ann Pharmacother; 2011 Sep; 45(9):1061-6. PubMed ID: 21852592
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of Lubiprostone in Patients with Opioid-Induced Constipation: Phase 3 Study Results and Pooled Analysis of the Effect of Concomitant Methadone Use on Clinical Outcomes.
Spierings ELH; Drossman DA; Cryer B; Mazen Jamal M; Losch-Beridon T; Mareya SM; Wang M
Pain Med; 2018 Jun; 19(6):1184-1194. PubMed ID: 29016868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
